Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingqing Ding

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Cancer Research|January 14, 2016
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 DegradationChia-Wei Li, Weiya Xia, Seung-Oe Lim, et al.
The Journal of Clinical Investigation|October 12, 2011
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasisQingqing Ding, Chun-Ju Chang, Xiaoming Xie, et al.
Nature Cell Biology|January 22, 2008
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradationJer-Yen Yang, Cong S Zong, Weiya Xia, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
Investigational New Drugs|April 12, 2023
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapyNour Abuhadra, Ryan Sun, Roland L Bassett, et al.
Cancer Cell|March 24, 2012
The crosstalk of mTOR/S6K1 and Hedgehog pathwaysYan Wang, Qingqing Ding, Chia-Jui Yen, et al.
Therapeutic Advances in Medical Oncology|August 7, 2023
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimensHui Chen, Qingqing Ding, Laila Khazai, et al.
Breast Cancer Research : BCR|May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancerSahil Seth, Clinton Yam, Lei Huo, et al.
The Journal of Clinical Investigation|June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer modelsMei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Cancer Research|January 14, 2016
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 DegradationChia-Wei Li, Weiya Xia, Seung-Oe Lim, et al.
The Journal of Clinical Investigation|October 12, 2011
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasisQingqing Ding, Chun-Ju Chang, Xiaoming Xie, et al.
Nature Cell Biology|January 22, 2008
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradationJer-Yen Yang, Cong S Zong, Weiya Xia, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
Investigational New Drugs|April 12, 2023
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapyNour Abuhadra, Ryan Sun, Roland L Bassett, et al.
Cancer Cell|March 24, 2012
The crosstalk of mTOR/S6K1 and Hedgehog pathwaysYan Wang, Qingqing Ding, Chia-Jui Yen, et al.
Therapeutic Advances in Medical Oncology|August 7, 2023
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimensHui Chen, Qingqing Ding, Laila Khazai, et al.
Breast Cancer Research : BCR|May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancerSahil Seth, Clinton Yam, Lei Huo, et al.
The Journal of Clinical Investigation|June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer modelsMei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
Pageof 14